Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

NCT02111577 is registered in ClinicalTrials.gov with SOTIO a.s. as lead sponsor.

NCT NCT02111577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02111577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Lead sponsor
SOTIO a.s.
Phase
Phase 3
Overall status
Completed
Start date
May 26, 2014
Completion date
January 28, 2020
Enrollment
1,182 (actual)
Sites
177

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer